India Pharma Outlook Team | Saturday, 23 August 2025
Indian pharma major Aurobindo Pharma is reportedly in talks to buy drugmaker Zentiva based in Prague for an estimated price of as much as $5.5 billion. If completed, it would be the largest overseas acquisition by an Indian pharma company.
Aurobindo Pharma, based in Hyderabad, is in discussions with Advent International, a US-based private equity company that owns Zentiva. While discussions are taking place, Aurobindo has disclosed in a filing to stock exchanges that its board has yet to enter any binding agreement.
The deal follows Aurobindo's bold move in July, when its subsidiary based in the US, Aurobindo Pharma USA Inc., entered into a definitive agreement to acquire Lannett Company LLC's 100% membership interest. These two transactions speak to Aurobindo's penchant for pursuing an aggressive strategy of global expansion.
Aurobindo Pharma, one of the leading pharmaceutical companies in India, develops and manufactures a huge range of generic pharmaceuticals, branded specialty products and active pharmaceutical ingredients (APIs). It sells its products in over 150 countries, supplying a full line of value-based generic medication from 30 high-tech manufacturing and packaging sites in accordance with global regulatory authority standards e.g., USFDA, UK MHRA, Japan PMDA, WHO, Health Canada.
Also Read: Alcon launches UNITY surgical platforms in India
The company's therapeutic presence includes segments such as central nervous system (CNS), anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetic and anti-allergic, fulfilling these therapeutic areas of focus with a robust Research and Development dimension. If the acquisition of Zentiva is successful, Aurobindo will enhance its position in the European generics market, gaining scale, diversified revenues and manufactured goods with substantial access to recent developments in manufacturing.
Furthermore, it underscores the increasing aspirations of many Indian pharmaceutical companies to compete on the world stage, and sets India into an evolving role as a larger contributor in the global healthcare supply chain.
